1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. Available here: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf;
2. Avdeev S, et al. Int J COPD 2019; 14:1267–1280;
3. Kew KM, Seniukovich A. Cochrane Database Syst Rev 2014; 3:CD010115;
4. Beeh KM, et al. Int J COPD 2016; 11:193–205.

This study was supported by Boehringer Ingelheim. Sarah Amir, PhD, at MediTech Media provided editorial assistance in the development of this poster, funded by Boehringer Ingelheim. The authors would like to thank all the patients for participating in these trials, and they also extend their thanks to the investigators.

JKQ’s research group has received funds via Imperial Consultants. JM, LW and AdlH are employees of Boehringher Ingelheim. DE, XH and LK are employees of HealthCore Inc, which received funding from Boehringer Ingelheim to conduct the study. MM has received personal fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, AstraZeneca, Teva, Grifols, Novartis, Gebro Pharma, CSL Behring, Cipla, MedImmune, Mereo BioPharma and Sandoz.